Suppr超能文献

组蛋白去乙酰化酶抑制剂、抗癌机制及胃肠道癌治疗

Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.

作者信息

Fang Jing Yuan

机构信息

Shanghai Second Medical University Renji Hospital, Shanghai Institute of Digestive Disease, China.

出版信息

J Gastroenterol Hepatol. 2005 Jul;20(7):988-94. doi: 10.1111/j.1440-1746.2005.03807.x.

Abstract

Histone acetylation regulates gene transcription. Histone acetylation is a reversible process: histone acetyltransferases (HAT) transfer the acetyl moiety from acetyl coenzyme A to the lysine, and histone deacetylases (HDAC) remove the acetyl groups re-establishing the positive charge in the histones. HDAC inhibitors have antiproliferative activity against human cancer cells via cell cycle arrest, pro-differentiation, and pro-apoptosis. In recent years, many studies have shown that specific HDAC inhibitors are helpful for gastrointestinal cancer therapy.

摘要

组蛋白乙酰化调节基因转录。组蛋白乙酰化是一个可逆过程:组蛋白乙酰转移酶(HAT)将乙酰辅酶A中的乙酰基转移到赖氨酸上,而组蛋白去乙酰化酶(HDAC)则去除乙酰基,重新在组蛋白中建立正电荷。HDAC抑制剂通过细胞周期阻滞、促分化和促凋亡对人类癌细胞具有抗增殖活性。近年来,许多研究表明特定的HDAC抑制剂有助于胃肠道癌症治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验